Under construction – not a live service
Sign in
Taking people in ChinaPhase 3

Donanemab for Chinese people at risk of Alzheimer's disease before memory problems appear

Tests donanemab against placebo in Chinese adults at risk of Alzheimer's decline.

Key facts

Who runs it
Eli Lilly and Company
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jiaxing, Jinan, Nanchang, Nanjing, Nanyang, Shanghai, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Xi'an, Xianyang, Xining, Zigong, and Zunyi, ChinaSee the 30 sites
Trial code
Registry title
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
Status
Recruiting
Phase
Phase 3
People taking part
140 people, planned
Started
30 Apr 2026
Expected to end
Apr 2030
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Donanemab
  • Placebo
Record updated
24 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for Chinese adults aged 55 to 80 with no memory or thinking problems yet, but with signs of Alzheimer's disease in the blood.

Age
55 to 80 years
Sex
All sexes can join.
Disease stage
Early (preclinical) Alzheimer's disease: normal thinking and memory (TICS-M score of 35 or higher, CDR-GS of 0).
Earlier treatment
People who had a vaccine or antibody treatment against amyloid beta in another study, or who use or used prescription medicines for mild cognitive impairment or Alzheimer's disease, cannot join.
Biomarker or test result
A blood plasma P-tau result that fits amyloid disease in the brain.

Main reasons for not taking part

  • Mild cognitive impairment, dementia or another serious brain disease that affects thinking
  • Serious or unstable illness that could affect the study or limit life expectancy to 5 years or less
  • Cannot have an MRI scan, for example because of a pacemaker, stent, cochlear implant or other metal implant
  • Certain brain MRI findings, such as ARIA-E, more than 4 tiny brain bleeds, any larger brain bleed, or severe white matter disease
  • No reliable study partner who knows them well and can answer questions about daily life

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • A Telephone Interview for Cognitive Status - Modified (TICS-M) score indicative of intact cognitive function (cut-off score of 35 or higher)
  • Clinical Dementia Rating-Global Score (CDR-GS) of 0
  • A plasma P-tau result consistent with amyloid pathology
  • A reliable study partner who:; Provides written informed consent to participate in the study in their role; Has frequent contact with the participant and is familiar with their overall function and behavior, including daily activities and cognitive abilities; Is of legal age (18 years of age or older) to consent; Is available to conduct functional scales
  • Have adequate literacy, vision, and hearing for neuropsychological testing

Who cannot take part

  • Have received active or passive immunization against amyloid beta (Aβ) in any other study
  • Have current or prior use of prescription medications for treatment of MCI or AD
  • Have mild cognitive impairment (MCI), dementia, or other significant neurodegenerative diseases that could affect cognition
  • Have a serious or unstable illness (including cardiovascular, hepatic, renal, gastrointestinal, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease, or other condition) that, in the investigator's opinion, could interfere with study analyses or result in a life expectancy of 5 years or fewer
  • Have any contraindications for magnetic resonance imaging (MRI), including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants or other accessory medical devices, such as cardiac pacemakers, stents, and cochlear implants
  • Have a centrally read magnetic resonance imaging (MRI) demonstrating the presence of Amyloid-related imaging abnormalities (ARIA-E), more than 4 cerebral microhemorrhages, more than 1 area of cortical superficial siderosis, any macrohemorrhage (that is, intracerebral hemorrhage more than 1 cm), or severe white matter disease at screening

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 55 and 80 years old?

Where in China

  • Peking University Third HospitalBeijing, ChinaContact: Qiong Yang (principal investigator)Taking people
  • The First Hospital of Jilin UniversityChangchun, ChinaContact: Li Sun (principal investigator)Taking people
  • Xiangya Hospital Central South UniversityChangsha, ChinaContact: Lu Shen (principal investigator)Taking people
  • Sichuan Provincial People's HospitalChengdu, ChinaContact: Nengwei Yu (principal investigator)Taking people
  • 2nd Affiliated Hospital Chongqing Medical UniversityChongqing, ChinaContact: Xiaofeng Li (principal investigator)Taking people
  • The First Affiliated Hospital of Chongqing Medical UniversityChongqing, ChinaContact: Yang Lv (principal investigator)Taking people
  • Fujian Medical University Union HospitalFuzhou, ChinaContact: Jiawei Xin (principal investigator)Taking people
  • Guangdong Provincial People's HospitalGuangzhou, ChinaContact: jiehao zhao (principal investigator)Taking people
  • Anhui Provincial HospitalHefei, ChinaContact: Zhaozhao Cheng (principal investigator)Taking people
  • The Second Hospital of JiaxingJiaxing, ChinaContact: Yanping Wang (principal investigator)Taking people
  • Jinan Central HospitalJinan, ChinaContact: Hong Bian (principal investigator)Taking people
  • The Second Affiliated Hospital of Nanchang UniversityNanchang, ChinaContact: Zhenyu Tang (principal investigator)Taking people
  • Jiangsu Province Official HospitalNanjing, ChinaContact: Kezhong Zhang (principal investigator)Taking people
  • Nanjing Brain HospitalNanjing, ChinaContact: Weiwei Jiang (principal investigator)Taking people
  • Sir Run Run Hospital of Nanjing Medical UniversityNanjing, ChinaContact: Xiang Lu (principal investigator)Taking people
  • The First Affiliated Hospital of Nanyang Medical CollegeNanyang, ChinaContact: Qian Deng (principal investigator)Taking people
  • Huashan Hospital, Fudan UniversityShanghai, ChinaContact: Jintai Yu (principal investigator)Taking people
  • Pudong New Area People's Hospital ShanghaiShanghai, ChinaContact: Xiaohui Zhao (principal investigator)Taking people
  • Renji Hospital Shanghai Jiao Tong University School of MedicineShanghai, ChinaContact: Gang Wang (principal investigator)Taking people
  • Shanghai East HospitalShanghai, ChinaContact: You Yin (principal investigator)Taking people
  • Shanghai Sixth People's HospitalShanghai, ChinaContact: Qihao Guo (principal investigator)Taking people
  • Shenzhen People's HospitalShenzhen, ChinaContact: Liangyu Zou (principal investigator)Taking people
  • The First Hospital of Hebei Medical UniversityShijiazhuang, ChinaContact: Xiaowei Ma (principal investigator)Taking people
  • Tianjin Medical University General HospitalTianjin, ChinaContact: Li Yang (principal investigator)Taking people
  • The First Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaContact: Zhen Wang (principal investigator)Taking people
  • Shaanxi provincial people's hospitalXi'an, ChinaContact: Rui Li (principal investigator)Taking people
  • Xianyang Hospital of Yan'an UniversityXianyang, ChinaContact: Aihong Guo (principal investigator)Taking people
  • Qinghai Provincial People's HospitalXining, ChinaContact: Xin Zhong (principal investigator)Taking people
  • Zigong First People's HospitalZigong, ChinaContact: Xiaoya Xu (principal investigator)Taking people
  • Zunyi First People's HospitalZunyi, ChinaContact: Fei Feng (principal investigator)Taking people

About the trial

What the trial wants to find out

The main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living from Alzheimer's disease (AD).

Read full original descriptionShow less

The study drug will be administered intravenously (IV) (into a vein in the arm).

The study will last up to approximately 156 weeks, excluding screening.

The 2 groups in the trial

  • DonanemabTreatment being tested

    Donanemab administered intravenously (IV)

  • PlaceboPlacebo, for comparison

    Placebo administered IV

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Study of Donanemab Versus Placebo in Chinese Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Plain-language title
Donanemab for Chinese people at risk of Alzheimer's disease before memory problems appearGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07571161, who can take part
Record updated
24 August 2026